Dr. John Beutler

Dr. Beutler has identified several natural products which have potential for development as cancer drugs, among them, englerins, which are in preclinical development for kidney cancer and Ewing’s sarcoma, schweinfurthins, which are preclinical candidates in glioblastoma and malignant peripheral nerve sheath tumors, and salicylihalamides, of interest in sarcomas. As a Staff Scientist 2, Dr. Beutler oversees the Program's high-throughput screening libraries, information technology, and drug development efforts.